Standard therapeutic doses for diabetes typically range from 0.5 mg to 2 mg weekly for semaglutide (with Wegovy dosing up to 2.4 mg weekly for obesity), though lower doses are used during initial titration to minimize gastrointestinal side effects
These labs typically include an obesity lab panel, which measures CBC (blood count), CMP (metabolic function), lipids (cholesterol levels), A1C (diabetes), TSH (thyroid function), and insulin
active pulmonary disease, including chronic obstructive pulmonary disease, pulmonary fibrosis, moderate-to-severe sleep apnea and moderate-to-severe asthma
Here are our results: Approval speed: We ordered on January 19th and were approved the same day
This outcome positions retatrutide as a highly effective candidate, potentially more so than current treatments like semaglutide (Wegovy) and tirzepatide (Zepbound)
These include behavioral therapy, nutritional guidance, and assistance in developing a regular exercise regime